These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36601751)

  • 1. Clinical and pathological characterization of ophthalmic disease in a canine model of mucopolysaccharidosis type I.
    Nenninger A; Ben-Shlomo G; Allbaugh R; Valentine B; Snella E; Jens J; Ellinwood NM; Smith J
    J Inherit Metab Dis; 2023 Mar; 46(2):348-357. PubMed ID: 36601751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocular lesions in canine mucopolysaccharidosis I and response to enzyme replacement therapy.
    Newkirk KM; Atkins RM; Dickson PI; Rohrbach BW; McEntee MF
    Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):5130-5. PubMed ID: 21436264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progressive eye pathology in mucopolysaccharidosis type I mice and effects of enzyme replacement therapy.
    Gonzalez EA; Visioli F; Pasqualim G; de Souza CFM; Marinho DR; Giugliani R; Matte U; Baldo G
    Clin Exp Ophthalmol; 2020 Apr; 48(3):334-342. PubMed ID: 31925897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I.
    Dickson P; Peinovich M; McEntee M; Lester T; Le S; Krieger A; Manuel H; Jabagat C; Passage M; Kakkis ED
    J Clin Invest; 2008 Aug; 118(8):2868-76. PubMed ID: 18654665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intra-articular enzyme replacement therapy with rhIDUA is safe, well-tolerated, and reduces articular GAG storage in the canine model of mucopolysaccharidosis type I.
    Wang RY; Aminian A; McEntee MF; Kan SH; Simonaro CM; Lamanna WC; Lawrence R; Ellinwood NM; Guerra C; Le SQ; Dickson PI; Esko JD
    Mol Genet Metab; 2014 Aug; 112(4):286-93. PubMed ID: 24951454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I.
    Kakkis E; McEntee M; Vogler C; Le S; Levy B; Belichenko P; Mobley W; Dickson P; Hanson S; Passage M
    Mol Genet Metab; 2004; 83(1-2):163-74. PubMed ID: 15464431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I.
    Dierenfeld AD; McEntee MF; Vogler CA; Vite CH; Chen AH; Passage M; Le S; Shah S; Jens JK; Snella EM; Kline KL; Parkes JD; Ware WA; Moran LE; Fales-Williams AJ; Wengert JA; Whitley RD; Betts DM; Boal AM; Riedesel EA; Gross W; Ellinwood NM; Dickson PI
    Sci Transl Med; 2010 Dec; 2(60):60ra89. PubMed ID: 21123810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I.
    Kakkis ED; McEntee MF; Schmidtchen A; Neufeld EF; Ward DA; Gompf RE; Kania S; Bedolla C; Chien SL; Shull RM
    Biochem Mol Med; 1996 Aug; 58(2):156-67. PubMed ID: 8812735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucopolysaccharidosis type I.
    Wraith JE; Jones S
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():102-6. PubMed ID: 25345091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neonatal tolerance induction enables accurate evaluation of gene therapy for MPS I in a canine model.
    Hinderer C; Bell P; Louboutin JP; Katz N; Zhu Y; Lin G; Choa R; Bagel J; O'Donnell P; Fitzgerald CA; Langan T; Wang P; Casal ML; Haskins ME; Wilson JM
    Mol Genet Metab; 2016 Sep; 119(1-2):124-30. PubMed ID: 27386755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene therapy for canine alpha-L-iduronidase deficiency: in utero adoptive transfer of genetically corrected hematopoietic progenitors results in engraftment but not amelioration of disease.
    Lutzko C; Omori F; Abrams-Ogg AC; Shull R; Li L; Lau K; Ruedy C; Nanji S; Gartley C; Dobson H; Foster R; Kruth S; Dubé ID
    Hum Gene Ther; 1999 Jun; 10(9):1521-32. PubMed ID: 10395377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type I.
    Dickson PI; Hanson S; McEntee MF; Vite CH; Vogler CA; Mlikotic A; Chen AH; Ponder KP; Haskins ME; Tippin BL; Le SQ; Passage MB; Guerra C; Dierenfeld A; Jens J; Snella E; Kan SH; Ellinwood NM
    Mol Genet Metab; 2010; 101(2-3):115-22. PubMed ID: 20655780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corneal opacity in canine MPS I. Changes after bone marrow transplantation.
    Constantopoulos G; Scott JA; Shull RM
    Invest Ophthalmol Vis Sci; 1989 Aug; 30(8):1802-7. PubMed ID: 2503461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow transplantation in canine mucopolysaccharidosis I. Effects within the central nervous system.
    Shull RM; Hastings NE; Selcer RR; Jones JB; Smith JR; Cullen WC; Constantopoulos G
    J Clin Invest; 1987 Feb; 79(2):435-43. PubMed ID: 3100576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of bone marrow transplantation in dogs with mucopolysaccharidosis I.
    Breider MA; Shull RM; Constantopoulos G
    Am J Pathol; 1989 Mar; 134(3):677-92. PubMed ID: 2493739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arterial pathology in canine mucopolysaccharidosis-I and response to therapy.
    Lyons JA; Dickson PI; Wall JS; Passage MB; Ellinwood NM; Kakkis ED; McEntee MF
    Lab Invest; 2011 May; 91(5):665-74. PubMed ID: 21383673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of neonatal enzyme replacement therapy and simvastatin treatment on cervical spine disease in mucopolysaccharidosis I dogs.
    Chiaro JA; O'Donnell P; Shore EM; Malhotra NR; Ponder KP; Haskins ME; Smith LJ
    J Bone Miner Res; 2014 Dec; 29(12):2610-7. PubMed ID: 24898323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term nonsense suppression therapy moderates MPS I-H disease progression.
    Gunn G; Dai Y; Du M; Belakhov V; Kandasamy J; Schoeb TR; Baasov T; Bedwell DM; Keeling KM
    Mol Genet Metab; 2014 Mar; 111(3):374-381. PubMed ID: 24411223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MPS VI associated ocular phenotypes in an MPS VI murine model and the therapeutic effects of odiparcil treatment.
    Entchev E; Antonelli S; Mauro V; Cimbolini N; Jantzen I; Roussey A; Germain JM; Zhang H; Luccarrini JM; Lacombe O; Young SP; Feraille L; Tallandier M
    Mol Genet Metab; 2022 Feb; 135(2):143-153. PubMed ID: 34417096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrastromal Gene Therapy Prevents and Reverses Advanced Corneal Clouding in a Canine Model of Mucopolysaccharidosis I.
    Miyadera K; Conatser L; Llanga TA; Carlin K; O'Donnell P; Bagel J; Song L; Kurtzberg J; Samulski RJ; Gilger B; Hirsch ML
    Mol Ther; 2020 Jun; 28(6):1455-1463. PubMed ID: 32330426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.